Lifecare ASA: Mandatory notification of trade subscription of shares in rights issue

Reference is made to the stock exchange announcement published by Lifecare ASA (the "Company") on 7 January 2026 regarding the commencement of the subscription period in the partially underwritten rights issue (the "Rights Issue").

Subscription rights were allocated to existing shareholders as of 2 January 2026 (as registered in the VPS as of 6 January 2026). Each subscription right entitles the holder to subscribe for and be allocated one (1) new share at the subscription price in the Rights Issue of NOK 0.50 per share.

Subscribers in the Rights Issue will, without cost, receive warrants in two series: (a) three (3) warrants for every four (4) new shares allocated to, and paid by, them in the Rights Issue, which will be exercisable in the exercise period from 2 March 2026 to 13 March 2026 ("Warrants Series 1"); and (b) three (3) warrants for every four (4) new shares allocated to, and paid by them, in the Rights Issue, which will be exercisable in the exercise period from 1 June 2026 to 12 June 2026 ("Warrants Series 2" and together with Warrants Series 1, the "Warrants"). By subscribing for new shares in the Rights Issue, subscribers will at the same time subscribe for the corresponding number of Warrants.

Teigland Eiendom AS, a company closely associated with Trine Teigland, board member of the Company, has subscribed for 10,000,000 new shares in the Rights Issue through the exercise of subscription rights.

Further, in accordance with the terms of the Rights Issue, Teigland Eiendom AS has at the same time subscribed for in total 15,000,000 Warrants.

Please see the attached PDMR form for further details.

About us Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-01-22 10:12 CET.